[Clinico-microbiological assessment of therapeutic antifungal drugs therapeutic activity in patients with atopic dermatitis sensitized to yeast fungi].
OBJECTIVE
To study of therapeutic activity of local (natamycine) and systemic (fluconasol) antifungal drugs in patients with atopic dermatitis (AD) with mycogenic sensitization and candida carriage.


METHODS
29 patients with severe AD and diagnosed contamination of the skin lesions with yeast fungi have received antifungal treatment with fungicidal drugs in low-dose long-term course.


RESULTS
The drugs were effective in 83% of patients: poor effect was in 28%, moderate--in 21% and good--in 34% of cases. 5 (17%) patients did not respond. Mild, moderate and severe AD responded in 87, 36 and 60% of patients, respectively. The highest response was registered in patients without sensitization to yeast fungi (78%) or low sensitization (83%). In high sensitization the effect occurred in 57% of the cases.


CONCLUSIONS
The authors have developed indications for treatment with antifungal drugs in AD patients with mycogenic sensitization.
Mokronosova
M A
MA
Samuĭlova
T L
TL
Arzumanian
V G
VG
Sveranovskaia
V V
VV
Gervazieva
V B
VB
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D015169:Colony Count, Microbial; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007114:Immunization / Q000009:adverse effects*; D007223:Infant; D008875:Middle Aged; D010866:Natamycin / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D015003:Yeasts / Q000187:drug effects* / Q000254:growth & development / Q000276:immunology
D000935:Antifungal Agents; D010866:Natamycin; D015725:Fluconazole